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Abstract
In this brief review and perspective, we address the question of whether the immune
responses that bring about immune control of acute HIV infection are the same as, or dis-
tinct from, those that maintain long-term viral suppression once control of viremia has been
achieved. To this end, we describe the natural history of elite and post-treatment control,
noting the lack of data regarding what happens acutely. We review the evidence suggesting
that the two clinical phenotypes may differ in terms of the mechanisms required to achieve
and maintain control, as well as the level of inflammation that persists once a steady state is
achieved. We then describe the evidence from longitudinal studies of controllers who fail
and studies of biologic sex (male versus female), age (children versus adults), and simian
immunodeficiency virus (SIV) (pathogenic/experimental versus nonpathogenic/natural
infection). Collectively, these studies demonstrate that the battle between the inflammatory
and anti-inflammatory pathways during acute infection has long-term consequences, both
for the degree to which control is maintained and the health of the individual. Potent and
stringent control of HIV may be required acutely, but once control is established, the chronic
inflammatory response can be detrimental. Interventional approaches designed to bring
about HIV cure and/or remission should be nuanced accordingly.
Introduction
Identifying the mechanisms by which the host can naturally control HIV or simian immuno-
deficiency virus (SIV) has long been a priority for immunologists. These mechanisms might be
leveraged to develop novel interventions to prevent HIV transmission, control HIV in the
absence of therapy (a “remission”), or even fully eradicate the reservoir (a “cure”) [1]. Towards
this end, groups around the world have recruited and characterized those rare individuals who
maintain near-complete control of the virus in the absence of antiretroviral therapy (ART).
Two distinct clinical phenotypes exist: those who naturally control the virus without any treat-
ment (“elite” controllers) and those who do so but only after receiving prolonged ART (“post-
treatment controllers”).
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Most studies of elite and post-treatment controllers focused on those individuals who are
recruited during a period of long-term host-mediated control. Although often unstated, these
studies assume that those mechanisms that maintain control are the same as those that initially
brought the virus under control. This assumption is convenient but has limitations. In this
brief review and perspective, we challenge this assumption and argue that the optimal immune
response needed to achieve control differs from that needed to maintain control. Untangling
these mechanisms might be needed before we can develop effective prevention and curative
interventions.
Natural history of elite and post-treatment control
The natural history of individuals who are destined to fully control their virus in the absence
of therapy (elite control) or after interrupting therapy (post-treatment control) remains poorly
defined. This is particularly true during the immediate post-infection or post-interruption
period in which the virus likely replicates in the absence of a fully formed host response.
Because most controllers are identified long after the acute viremic phase has resolved, the
kinetics of HIV replication and the immediate host response are poorly understood.
Elite control
Depending on the definition, approximately 0.5% to 1% of untreated individuals eventually
achieve elite control [2]. Although the chronic steady-state biology of HIV control has been
well studied [3–6], little is known about the acute phase. Many, if not most, of these individuals
express the HLA-B�57:01 allele [7, 8]. HLA-B�57:01 has been reported to be under represented
in people presenting with acute infection, suggesting low levels of acute viremia and at least
partial control of the virus during this time [9]. In the prospective United States Department
of Defense HIV Natural History Study and the European-based Choices, Attitudes, and Strate-
gies for Care of Advand Dementia at the End-of-Life (CASCADE) cohorts, the level of viremia
in early infection was lower in controllers than noncontrollers, but data during the acute phase
were lacking [10, 11]. In the prospective Prediction of Muscular Risk in Observational condi-
tions (PRIMO) cohort, eight controllers were identified during early infection (median 2.2
months after infection) and were found on average to have low levels of viremia [12], but there
was substantial variability and no one was diagnosed in acute phase when peak viremia would
have occurred. Low levels of viremia during the acute and/or early phase have also been
reported in several case reports and small cohorts [13–19]. Although data from the acute phase
of peak viremia are scarce, the collective data suggest that peak viremia during the acute phase
is likely lower than that in more typical infection. Elite control is likely driven in part by a
favorable host response that is active during the earliest stages of the infection.
Given the challenges of studying acute infection in elite controllers, animal models may be
needed to advance this story. Elite control has been observed in SIV-infected macaques, partic-
ularly those carrying the MHC class I allele Mamu-B�08 or Mamu-B�17. Approximately 50%
and 25% of Mamu-B�08-positive and Mamu-B�17-positive macaques, respectively, achieve
control following infection with the highly pathogenic SIVmac239 [20, 21]. In humans
infected with HIV, the presence of protective HLA class I molecules such as HLA-B�57 and
HLA-B�27 are less predictive of control. This differential effect of protective alleles may be due
to the nature of the infection; macaques are experimentally infected with a single clone,
whereas humans are naturally infected by a huge diversity of viruses.
In the macaque model, viremia during the acute phase did not differ between those animals
with or without a protective class I allele type; monkeys with Mamu-B�08 had high-level vire-
mia before achieving control [20]. Transient but high-level viremia was also observed in other
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models of SIV control [22]. Therefore, the SIV model suggests that the host immune response
emerges quickly during acute infection but perhaps not until after a transient period of high
viremia. Whether this is true in humans remains unknown. The monkey model will likely be
needed to untangle the complex virus–host interactions that occur prior to the establishment
of elite control.
Post-treatment control
Since the first identification of the post-treatment control phenotype [23], the field has strug-
gled with how to define and study this relatively rare clinical phenotype [24]. There is even an
ongoing debate as to whether post-treatment controllers are simply elite controllers destined
to control their virus even without a period of ART [25, 26]; indeed, in the Short Pulse Anti-
Retroviral Therapy at Seroconversion (SPARTAC) cohort, the frequency of at least transient
control in the absence of therapy was not too different from the degree of transient control
among those who were treated early and then stopped [25].
Arguing for their legitimacy are the observations that the two clinical phenotypes of post-
treatment control and elite control are distinct in a number of important characteristics. The
frequency of post-treatment control among those starting and stopping ART in early infection
is higher than one might expect for natural control (approximately 5% to 20% versus 0.5% to
1%, depending on definitions) [23, 27–32]. The reservoir declines over time in some post-
treatment controllers but is remarkably stable in elite controllers [27, 33]. HIV-specific cluster
of differentiation (CD)8+ T-cell responses are generally low in post-treatment controllers but
high in elite controllers [27, 34, 35]. CD8+ T-cell activation (defined by co-expression of CD38
and HLA-DR) is lower in post-treatment controllers than elite controllers [27]. The distribu-
tion of class I HLA alleles may also be different, as described below.
As with elite controllers, there is a dearth of information regarding what happens during
the immediate post-treatment period when responsibility for virus control shifts from ART to
the host immune response. Perhaps the best data come from a recent study of a therapeutic
vaccine in which post-treatment control was relatively common in the control group [28]. In
this study of people who had started ART early, 4 of 15 (26%) subjects in the placebo arm and
2 of 14 (14%) in the vaccine arm had at least partial control for at least 16 weeks off therapy,
with 2 in the placebo arm exhibiting sustained control. Acute post-ART spikes in viremia were
initially observed in most of these controllers, with levels that were often but not universally
low (100 to 10,000 copies RNA/mL). Similar findings have been observed in a recent multi-
cohort study (the Control of HIV after Antiretroviral Medication Pause [CHAMP] cohort)
[36].
A critical question regarding post-treatment control is the degree to which ART fundamen-
tally switches the balance in favor of the host immune response. This question can be
addressed in part by comparing the pre-ART viral load with the level of post-ART control. The
pre-ART levels of viremia in post-treatment controllers have also been variable, with evidence
from two cohorts suggesting that a low viral load in acute infection predicts a low viral load
post-ART, although the effect was modest [12, 30]. In contrast, in the Viro-Immunologic Sus-
tained Control After Treatment Interruption (VISCONTI) cohort pre-ART viremia was
reported to be much higher in people destined to become post-treatment controllers than
those destined to become elite controllers [27]. Similarly, in the largest study of post-treatment
controllers identified to date (the CHAMP cohort), the level of viremia prior to ART was simi-
lar in individuals who controlled post-ART compared to those who failed to control post-ART
[32]. In contrast, the reservoir size (often estimated by frequency of HIV DNA levels in circu-
lating CD4+ T cells) has been reported to be low during ART in those who eventually achieve
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post-treatment control [27, 34, 37, 38]. These observations, which are admittedly based on
small numbers and incomplete data, suggest that ART can shift the host–virus balance towards
one that favors the host.
Mechanisms of elite control likely differ from those of post-
treatment control
A clue to the central mechanisms underlying elite control of HIV infection is the high fre-
quency of “protective” HLA molecules such as HLA-B�57 and HLA-B�27 and low frequency
of “disease-susceptible” HLA molecules such as HLA-B�35 [8, 39]. In contrast, in the VIS-
CONTI post-treatment controller cohort, HLA-B�35 was highly prevalent, and HLA-B�27 and
B�57 were notably infrequent [27]. In the SPARTAC study, the study cohort was a mixture of
subtype-B–infected male Caucasians and subtype-C–infected female Africans, and in this het-
erogeneous group, one or more disease-susceptible HLA alleles (defined as HLA-B�35:01 or
HLA-B�07:02 for subtype-B and HLA-B�18:01 or HLA-B�58:02 for subtype-C) were also
found in the post-treatment controllers, whereas there was no clear enrichment for the classic
protective alleles [25]. Classically defined protective alleles were rare in another recent cohort
of post-treament controllers [38]. Among post-treatment controllers, the ability of HIV-spe-
cific CD8+ T cells to inhibit viral replication is modest—and similar to that of typical non-con-
trollers—but significantly lower than that of elite controllers. This prompts the question of
whether those controlling HIV after treatment are doing so because of an immune response
that does not rely on generation and persistence of the immunodominant HLA-B-restricted
CD8+ T cell specificities observed in many elite controllers.
The differential distribution of HLA alleles in post-treatment control and elite control may
provide hints as to why levels of T-cell activation or inflammation are lower in the former
group, as has been described [27]. HLA molecules have unique binding affinity for the leuko-
cyte immunoglobulin-like receptors (LILRs), which are believed to play a regulatory role in
dendritic cell function. HLA alleles associated with elite control (HLA-B57 and HLA-B27)
enable the generation of aggressive, highly activated and immunodominant CD8+ T-cell
responses in acute infection [9, 40–42]. These HLA molecules have low binding affinity for the
LILRB2 receptor and hence induce less regulation of dendritic cells and ultimately greater acti-
vation of T cells. In contrast, HLA-B�35 has high binding affinity for LILRB2 and hence likely
induces a greater degree of dendritic cell tolerization and less robust induction of CD8+ T-cell
responses [43].
Collectively, these HLA stories argue that elite control is maintained via sustained and
highly potent HIV-specific CD8+ T-cell activity that is part of a highly activated and inflamma-
tory immune response, whereas post-treatment control is maintained via a less inflammatory
response that may be less dependent on these pathways. This is perhaps not surprising as the
pathway needed to achieve initial control is fundamentally different in these two very distinct
clinical presentations: the amount of “work” that the immune system needs to perform in get-
ting the virus under control is likely much higher in elite control (in which a naïve system is
generating a response during very high levels of HIV replication) versus post-treatment control
(in which an exposed system might be primed to respond well before high viremia emerges).
Less is known about the mechanisms associated with post-treatment control. Putative
immunologic correlates of control include T-cell function (particularly CD4+ T-cell
responses), natural killer (NK) cell function (noncytolytic activities have been observed) and
low T-cell activation (lower than that observed in natural control and during ART) [27].
Perhaps the most consistent correlate of post-treatment control is a low reservoir [27, 38].
Based on mathematical modeling, it has also been argued that the early initiation of ART
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prevents the establishment of a large reservoir and that, in this setting, a less effective host
response may be sufficient to maintain durable control after therapy is interrupted [44]. That
the early initiation of ART blunts the establishment of a large reservoir is now well accepted
[45–48]. Early therapy also protects immune function [49, 50], but if started too early, it might
prevent the generation of effective HIV-specific T-cell memory [42]. If therapy is delayed too
long, escape mutants are generated [51], the reservoir size becomes less manageable, and the
immune system is irreversibly damaged. Consistent with these results, treatment of “hyper-
acute” HIV infection (Fiebig 1) fails to cause post-treatment control [52, 53] whereas treatment
of long-term established infection is also rarely protective. Early ART (but not too early) may
be needed (Fig 1). The timing of ART in VISCONTI and other post-treatment controllers
largely supports this concept.
Limitations inherent in cross sectional studies of elite and post-
treatment controllers
The vast majority of mechanistic studies regarding HIV control in people are cross sectional in
nature. These studies have well-known limitations. Specifically, it is difficult, if not impossible,
to determine cause and effect. The study of host genetics and outcome partially addresses this
Fig 1. The time ART is initiated may prove to be critical determinant of post-treatment control. Treatment of “hyperacute”
HIV infection (Fiebig 1) may prevent the development of an effective immune response. During a subsequent treatment
interruption, the virus will rebound rapidly, and there will be limited chance for post-treatment control. In contrast, a delay in
treatment for too long will result in a generation of escape mutants, a large and difficult-to-control reservoir, and a damaged
immune system. ART, antiretroviral therapy; CTL, cytotoxic T lymphocyte.
https://doi.org/10.1371/journal.ppat.1007222.g001
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concern, as the genes were present before the infection and distinguishing cause and effect is
straightforward.
During low-reservoir states, either in elite control or post-treatment control, the activity of
the host response is expected to be low even if it is actively controlling the virus, complicating
the interpretation of any observations made during steady state. This dilemma is well illus-
trated by studies of extraordinary control of the virus in which the host responses were barely
detectable even though they were assumed to be active and effective [54]. The CD8+ T-cell
response during elite control is characterized as one with greater proliferative potential [55];
this suggests that the immune system is largely at rest and waiting to expand as needed when
infrequent bursts of replication occur. Nonactivated central memory CD8+ T cells that target
diverse epitopes and have the capacity to expand and differentiate are also enriched in elite
controllers [56, 57]. These cells are not abundant or particularly active, suggesting that they are
present in vivo but not being stimulated systemically. The nature of these responses is distinct
from the massive, high-magnitude, and apparently highly activated response typical of “hyper-
acute” HIV infection [41, 42].
There is no reason to assume that the pathways that gain control of HIV are not the same as
those that maintain control, but it is almost certainly true that once the control is gained, the
activity of these responses will decline, making it challenging to infer how the immune system
gained control in the first place. Still, longitudinal studies of the chronic phase will likely prove
informative in defining how best to maintain control (and perhaps avoid any collateral
damage).
Can we learn anything from controllers who eventually progress?
Chronic inflammation during elite control has been well-established [58–61]. These inflamma-
tory pathways likely contribute to immune dysfunction [62] and perhaps the development of
cardiovascular disease [63, 64].
Virologic rebound or progression among elite controllers is uncommon [11, 65–68] and
poorly understood. In one multinational observational study of individuals followed from
seroconversion (CASCADE), virus control (<500 copies RNA/mL) occurred in a small minor-
ity (1.4%) but once achieved was maintained in most (the probability of maintaining control
over 20 years was 0.74) [11]. In a multicenter study of controllers (Collaboration of Observa-
tional HIV Epidemiological Research Europe [COHERE]), progression was rare and was pre-
dicted by a low CD4/CD8 ratio and intermittent viremia [67]; similar findings were noted in a
French study [68]. In smaller pathogenesis-oriented studies, heightened inflammation and T-
cell activation predated and often predicted virologic progression [17, 69, 70].
The rates of virologic progression may be higher in post-treatment controllers than elite
controllers. In the CHAMP cohort, post-treatment controllers were identified from a collec-
tion of studies in which individuals were followed from the time they interrupted through at
least 24 weeks. The majority of those who controlled for at least 24 weeks (and hence met the
definition of a post-treatment controller) exhibited virologic rebound within three to four
years [32]; this rate is much higher than that reported in most elite controller cohorts. In the
SPARTAC cohort, there was a trend suggesting that those achieving control in the absence of
ART were more likely to maintain control than those who achieved it after an ART interrup-
tion [25].
The collective natural history studies suggest that post-treatment control is more common
than elite control but perhaps less durable. Two scenarios may explain these trends. Both clini-
cal phenotypes might involve the same mechanism, but a weaker one is sufficient to achieve
post-treatment but not elite control. Alternatively, distinct mechanisms underlie these clinical
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phenotypes, and those involved in post-treatment control work well in an acute setting (when
ART is interrupted) but not in a chronic setting (when control needs to be maintained
indefinitely).
Greater immune control of viremia but more rapid disease
progression among females
The natural history of untreated HIV infection differs by sex. In untreated infection, the viral
load set points in females are 0.33 to 0.78 log10 copies RNA/mL lower than in males [71].
Women are 5-fold more likely than men to be elite controllers [65]. Females are also more
likely than males to clear hepatitis C virus (HCV) in the absence of treatment [72]. Mechanisti-
cally, it has been argued that plasmacytoid dendritic cells (pDCs) in females produce substan-
tially more interferon-alpha in response to stimulation by toll-like receptor 7 (TLR7) ligands
such as HIV-1 and other single-stranded RNA viruses [73] (perhaps, as recently argued,
because TLR7 is on the X chromosome and is expressed at higher levels in females than males)
[74]. Although type I interferon has potent antiviral activities in the acute setting [75], too
much interferon-alpha, or too much of the wrong subtypes of interferon-alpha, can lead to
immune hyperactivation and its well-described detrimental consequences [76–81].
Although women may control HIV more often than men and have lower viral load set
points, women progress to AIDS at a more rapid rate for any given viral load than men [82].
High levels of immune activation for any given level of viremia may account for this apparent
accelerated progression in women [73]. Also, women have a greater tendency for viral rebound
after having achieved elite control [65]. Chronic inflammation has also been a consistent pre-
dictor of virus rebound among established controllers [17, 69, 70] and could contribute to
virologic progression through multiple mechanisms [83], as described below.
Collectively, these observations argue that immune response during acute infection is more
aggressive and effective in females compared with males. This does not come without a cost,
however, because this heightened inflammation during the chronic phase in females is associ-
ated with higher risk of losing virus control and progressing to AIDS. The consistent observa-
tion that women have much higher rates of a number of autoimmune diseases (e.g., systemic
lupus erythematosus [SLE], autoimmune thyroid disease, myasthenia gravis, rheumatoid
arthritis, multiple sclerosis, Sjogren syndrome, scleroderma) [84] is broadly consistent with
these observations. Theoretically, the potent anti-HIV response in females is more effective in
achieving initial control than that observed in males, but the possibly less inflammatory (or
more tolerant) response in males is more effective in maintaining control.
Pediatric versus adult HIV infection: Immunotolerance versus
immune aggression
In pediatric HIV infection, the ability of the immune system to control HIV via an effective
CD8+ T-cell response is largely neutered by the immunotolerant environment of early life [85,
86]. Consequently, viral loads are higher in children than adults; indeed, the median viral
loads are approximately 1.5 log10 higher in young children than in adults at the equivalent
time after infection [87, 88]. Elite control, as defined by having an undetectable viral load by
standard assays, is rare in perinatally infected children but has been reported [89, 90]. Post-
treatment control is also rare but has been reported [35, 91, 92].
In contrast to elite control, long-term non-progression is relatively common. At least 5% of
untreated HIV-infected children maintain normal-for-age CD4 counts through 5 to 10 years
of life with high levels of viremia (“viremic nonprogressors”) [93, 94]. This poorly researched
phenotype has been reported in adults but at frequencies much lower than those observed in
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007222 November 1, 2018 7 / 18
children [95–97]. Among children, nonprogression during high viremia has been associated
with low levels of T-cell activation in children. As children mature and become adolescents,
the steady-state levels of viremia decline while the levels of immune activation increase [93].
The children versus adult comparison is hence similar to the male versus female compari-
son among adults. The apparently more immunotolerant environment of young life seems to
prevent the immune system from achieving stringent control of HIV replication yet at the
same time protects against chronic inflammation, CD4+ T-cell loss, and disease progression.
Pathogenic versus nonpathogenic SIV infection
SIV infection of monkeys provides additional support for our model. The natural hosts for
SIV have low levels of immune activation and disease progression despite persistently high
viral loads [98, 99], a phenotype that is similar to human viremic nonprogressors [97]; indeed,
these two share a number of similar biologic profiles [95, 96]. Elite control in the natural hosts
for SIV is rare (most animals have viral loads well above 10,000 copies RNA/mL) although not
uncommon in experimental models such as rhesus macaques [20], in which the virus stimu-
lates a profound inflammatory response and causes rapid disease progression.
The double-edged sword effect of HLA-B*57 and HLA-B*27
HLA-B�57:01 is the single human genetic polymorphism most strongly associated with elite
control of HIV infection [7]. The mechanism for this protective effect has yet to be fully
defined. Many have argued that HLA-B�57, HLA-B�27, and other protective alleles present
multiple highly conserved epitopes for CD8+ T-cell recognition, escape from which results in
a significant fitness cost to the virus [100–102]. Perhaps the clearest evidence that epitope spec-
ificity is important is the observation that distinct protective class I alleles in rhesus macaques
(Mamu-B�17) and humans (HLA-B�27:02) target the identical immunodominant epitope
(Nef IW9 IRYPKTFGW in SIV and IRYPLTFGW in HIV) [103, 104] despite independent
evolution of human and rhesus macaque MHC class I. Similarly, the two protective alleles
Mamu-B�08 and HLA-B�27:05 share a similar peptide binding groove and can present the
identical epitopes [20]. It has also been reported that enhanced HIV-specific CD8+ T-cell
function—as defined by proliferative capacity, cytotoxic activities, and the production of mul-
tiple cytokines [5, 6]—has been a consistent predictor of virus control, arguing that the inher-
ent functional capacity of the immune response in addition to the epitopes targeted is a key
factor. This raises the possibility that HLA-B�57:01 and other protective alleles somehow stim-
ulate the generation of highly functional CD8+ T cells directly and independent of the epitopes
targeted [105].
Along these lines, HLA-B�57:01–restricted CD8+ T-cell response during acute infection is
notably more potent and sustained than other HLA-restricted responses [8, 106, 107] Also,
HLA-B�57:01 positivity is associated with the clearance of HCV [108], particularly in North
America [109].
The protective effects associated with HLA-B�57:01 positivity may come at a cost, however,
because this allele is associated with hypersensitivity reactions, most notably to abacavir [110].
Similarly, HLA-B�27:02 and HLA-B�27:05 are protective against HIV but also associated with
a long list of autoimmune disorders [111]. Many of the genes associated with protection
against HIV (including but not limited to HLA-B�57:01 and HLA-B�27) are associated with
higher risk of developing psoriasis among those with HIV and in the general popuation [112].
There is no unifying mechanism to explain the apparent connection between HLA,
immune control of HIV, and autoimmunity. A number of possibilities have been proposed,
including shared epitopes [112], unique thymic maturation pathways that result in a T cell
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receptor (TCR) repertoire that is broader and often more autoreactive [107] (and hence more
able to respond to escape mutants, another factor apparently associated with control [113–
115]), an ability to evade regulatory T-cell suppression [116], and a lack of dendritic cell regu-
lation due to poor binding avidity of HLA-B�57 and HLA-B�27 with LILRB2 [43], as described
above.
A recent set of observations regarding the complex interaction between HLA molecules
and NK cell receptors provides another potential mechanism by which particular HLA mole-
cules might substantially modulate the impact of the innate immune response. KIR3DL1 is
expressed on NK cells and, when engaged, inhibits the function of these cells. HLA molecules
bind killer cell immunoglobulin-like receptors (KIRs) and influence NK cell function in com-
plex ways. HLA-B�57:01 is the strongest binder to KIR3DL1 of all HLA allotypes tested [117].
People expressing both HLA-B�57:01 and specific allotypes of KIR3DL1 are more likely to
control HIV than those expressing just HLA-B�57:01 [118]. Co-expression of the KIR3DL1
variant, I47V, further enhances the protective effect of HLA-B�57:01 [119]. The mechanism
for this interaction between HLA and KIR molecules is unknown. One possibility is that NK
cells expressing high levels of KIR3DL1 are licenced to kill HIV-1-infected target cells directly
[120] and are unleashed by altered HLA-B�57:01 and/or peptide expression arising in the
HIV-infected targets [121]. Alternatively, NK cells regulate antiviral CD8 T-cell responses, the
presence of NK cells expressing inhibitory KIRs improving CD8+ T-cell function [122]. A fur-
ther possibility is that KIRs expressed on CD8+ T-cell surface may compete with TCRs that
recognize the same peptide–HLA-B�57:01 complex. Alterations in any of these pathways could
conceivably result in collateral effects and higher or lower risk of autoimmune and hypersensi-
tivity response.
Regardless of the mechanism, the HLA-B�57 and HLA-B�27 riddles once again illustrate
that, although the capacity to generate a potent inflammatory response might be helpful in
clearing or controlling a pathogen, this intrinsic capacity could also lead inflammation-associ-
ated harm.
Concluding remarks
As has been consistently demonstrated in studies of SIV and HIV, potent and sustained
immune responses to chronic pathogens cause collateral damage. Those who are more likely
to achieve elite control are in general more likely to experience disease progression, as shown
by our comparisons of women versus men, adults versus children, and natural versus experi-
mental models of SIV (Fig 2). The most robust predictors of virus control in untreated disease
are also consistently associated with autoimmunity and other inflammatory disorders. Longi-
tudinally, once elite control is achieved, those individuals who exhibit higher levels of inflam-
mation are more likely to lose control over time.
Why might chronic inflammation during periods of virus control eventually cause virologic
rebound? Theoretically, inflammation may enhance virus production and/or result in greater
numbers of susceptible targets for the virus (activated CD4+ T cells), leading to more virus
spread [83]. Alternatively, the persistent inflammation can result in a sustained counter-regu-
latory responses and inhibition of T-cell function, a phenomenon that has been observed in
cancer tissues and is now being targeted by a variety of immune therapies [123]. Up-regulation
of programmed cell death protein 1 (PD-1) and other checkpoint receptors, induction and
expansion of immunosuppressive cell populations (T regulatory cells, myeloid-derived sup-
pressor cells), and the expression of potent immunosuppressive pathways (indoleamine
2,3-dioxygenase, interleukin 10 [IL-10], and transforming growth factor beta [TGFß]) are all
associated with HIV-mediated inflammation. All are now being modified in experimental
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oncology, and many are being targeted in HIV cure strategies [124]. Similarly, activation of
TLR-mediated type I interferon signalling is currently being pursued as a means to reverse
latency and stimulate sustained immune responses [125, 126].
The recent success of canakinumab, an inhibitor of the inflammatory IL-1ß pathway, in
preventing cardiovascular disease progression and cancer provides proof of concept that
chronic inflammation is harmful and can be targeted therapeutically [127, 128]. The fact that
blocking this pathway also increased the risk for infectious disease complications highlights
the “double-edged sword” problem that we argue here will always need to be addressed in the
context of an HIV cure or remission strategy [129].
Fig 2. Favorable immune responses in order to achieve control of viremia in acute infection and in order to maintain control once achieved as in post-treatment
control. (A) Favorable immune responses to achieve control in acute infection. (B) Favorable immune responses to maintain virus control once achieved. SIV, simian
immunodeficiency virus.
https://doi.org/10.1371/journal.ppat.1007222.g002
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The HIV cure agenda is expanding. Many, if not most, of the approaches now in the clinic
seek to achieve long-term control of a replication-competent reservoir (a “remission”). Many
of these approaches have relied on studies of elite and post-treatment controllers as the inspira-
tion and even as a road map, but perhaps a more nuanced approach may be needed. It seems
that a more holistic approach might be better achieved by examining those states of control
that are more durable and less inflammatory in nature.
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